Trial Profile
Phase II Trial of Brostallicin and Cisplatin in Patients With Metastatic Triple Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Brostallicin (Primary) ; Cisplatin (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 06 Apr 2018 Status changed from active, no longer recruiting to completed.
- 13 Jun 2013 Final results presented at ASCO 2013.
- 26 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.